SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fermenta Biotech - Quaterly Results

08 Nov 2023 Evaluate
The sales for the September 2023 quarter moved down -43.07% to Rs. 513.09 millions as compared to Rs. 901.22 millions during the year ago period.The Net Loss for the quarter ended September 2023 is Rs. -279.84 millions as compared to Net Profit of Rs. 21.16 millions of corresponding quarter ended September 2022Operating profit Margin for the quarter ended September 2023 slipped to -95.92% as compared to 138.09% of corresponding quarter ended September 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 513.09 901.22 -43.07 1280.84 1745.76 -26.63 3289.20 3879.61 -15.22
Other Income 20.26 25.95 -21.93 40.80 64.93 -37.16 75.60 75.26 0.45
PBIDT -95.92 138.09 -169.46 56.47 256.96 -78.02 463.57 834.63 -44.46
Interest 37.16 48.67 -23.65 84.73 93.48 -9.36 209.42 172.26 21.57
PBDT -223.08 89.42 -349.47 -118.26 163.48 -172.34 -341.74 662.37 -151.59
Depreciation 56.76 62.48 -9.15 113.69 124.45 -8.65 245.14 236.74 3.55
PBT -279.84 26.94 -1138.75 -231.95 39.03 -694.29 -586.88 425.63 -237.89
TAX 0.00 5.78 0.00 0.00 7.37 -100.00 -11.55 123.25 -109.37
Deferred Tax 0.00 1.04 0.00 0.00 -0.03 0.00 0.00 49.18 0.00
PAT -279.84 21.16 -1422.50 -231.95 31.66 -832.63 -575.33 302.38 -290.27
Equity 144.37 144.24 0.09 144.37 144.24 0.09 144.29 144.24 0.03
PBIDTM(%) -18.69 15.32 -222.01 4.41 14.72 -70.05 14.09 21.51 -34.49

Fermenta Biotech Share Price

312.55 -9.30 (-2.89%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×